Inflazyme Pharmaceuticals Ltd. Announces Preliminary Outcome Of The Phase 2b CAPSICS Asthma Trial

January 30, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- January 29, 2007 -- Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it has completed the Phase 2b asthma clinical study in moderate to severe patients and the data has been unblinded.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II